

Guillain-Barre Syndrome Therapeutic Pipeline Market Review, H2 2016

Guillain-Barre Syndrome Treatment Pipeline Review H2 2016

PUNE, INDIA, October 13, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Guillain-Barre Syndrome](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and

press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/477408-guillain-barre-syndrome-pipeline-review-h1-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome
- The report reviews pipeline therapeutics for Guillain-Barre Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Guillain-Barre Syndrome therapeutics and enlists all their



WISE GUY
R E P O R T S

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

major and minor projects

- The report assesses Guillain-Barre Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Guillain-Barre Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Guillain-Barre Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=477408

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Guillain-Barre Syndrome Overview 6

Therapeutics Development 7

Pipeline Products for Guillain-Barre Syndrome - Overview 7

Pipeline Products for Guillain-Barre Syndrome - Comparative Analysis 8

Guillain-Barre Syndrome - Therapeutics under Development by Companies 9

Guillain-Barre Syndrome - Therapeutics under Investigation by Universities/Institutes 10

Guillain-Barre Syndrome - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Guillain-Barre Syndrome - Products under Development by Companies 14

Guillain-Barre Syndrome - Products under Investigation by Universities/Institutes 15

Guillain-Barre Syndrome - Companies Involved in Therapeutics Development 16

Akari Therapeutics, Plc 16

Alexion Pharmaceuticals, Inc. 17

Regenesance BV 18

Takeda Pharmaceutical Company Limited 19

Guillain-Barre Syndrome - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Coversin - Drug Profile 29
...Continued

Access Report @ <https://www.wiseguyreports.com/reports/477408-guillain-barre-syndrome-pipeline-review-h1-2016>

Follow Us:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.